Clinical trial
Expanded Access Programme of PEGASYS® (Peg Interferon Alpha-2a 40KD) in Patients With HBe-Ag-negative Chronic Hepatitis B
NCT01787279 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Expanded Access Programme of PEGASYS® (Peg Interferon Alpha-2a 40KD) in Patients With HBe-Ag-negative Chronic Hepatitis B
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 31, 2006
- Completion date
- May 31, 2009
- Enrollment
- 59 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.